Actively Recruiting

Age: 18Years +
All Genders
NCT04476563

Checkpoint Inhibitor-induced Liver Injury

Led by University of Nottingham · Updated on 2026-03-24

160

Participants Needed

1

Research Sites

298 weeks

Total Duration

On this page

Sponsors

U

University of Nottingham

Lead Sponsor

P

Pfizer

Collaborating Sponsor

AI-Summary

What this Trial Is About

In this multi-center prospective observational study, the investigators plan to identify the incidence and risk factors for checkpoint inhibitor-induced liver injury and characterize biochemical, genetic, immunological, and histological features associated with it.

CONDITIONS

Official Title

Checkpoint Inhibitor-induced Liver Injury

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to give written informed consent OR have a personal or nominated consultee if unable due to encephalopathy from ChILI
  • Patients who developed checkpoint inhibitor-induced liver injury meeting one of the following at enrollment: ALT >5 times upper limit of normal (ULN), OR ALT >3 times ULN plus bilirubin >2 times ULN, OR ALP >2 times ULN with elevated gamma-glutamyl transferase without bone metastases
  • No other known causes of liver injury after thorough investigations
  • Consecutive cancer patients with clinical indication to start checkpoint inhibitors (control group)
Not Eligible

You will not qualify if you...

  • Patients treated with cytotoxic chemotherapy concurrently with checkpoint inhibitors
  • Patients judged by chief investigator to have alternative explanations for acute liver injury other than ChILI
  • Patients who developed ChILI but did not meet the specified liver enzyme criteria or were found to have other causes after investigations

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Nottingham

Nottingham, United Kingdom, NG72RD

Actively Recruiting

Loading map...

Research Team

G

Guruprasad Padur Aithal, MBBS, FRCP, PhD

CONTACT

E

Edmond Atallah, M.D, MRCP(UK)

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here